Stealthy Atia Medical said it raised $5 million in a Series B round, with the 1st $3 million tranche coming from Medvance Incubator Partners.
Atia Medical is a portfolio company of Campbell, Calif.-based medical device incubator Shifamed, which formed early-stage medtech venture fund Medvance with partner Delos Capital, according to a press release.*
"We are grateful for Medvance Incubator Partners’ support so that we may remain focused on product development," Atia Medical CEO Mariam Maghribi said in prepared remarks.
Although the company is tight-lipped about its technology, in August 2014 Shifamed applied for a U.S. patent for a hydrophilic "accommodating" intraocular lens. The device is comprised of 2 lenses and an adhesive portion between the lenses that forms a fluid chamber, according to the patent.
Shifamed’s application for the Atia trademark listed the development of intraocular lenses as its "goods & services" area.
And Claudio Argento, listed as an inventor on the patent, is a member of Shifamed’s research & development team, according to Shifamed’s website. Argento was previously a senior director of R&D at PowerVision Lens, where he lead in the development of an accommodating intraocular lens. Argento’s previous work included a system for delivery of intraocular lenses into an eye, filed with PowerVision and approved in February.
*Correction, May 21, 2015: This article originally mis-stated Shifamed’s location. It is not based in Israel. We regret the error. Return to the corrected sentence.
